Association of Smoking and ALK Tyrosine-kinase Inhibitors on Overall Survival in Treatment-naïve ALK-positive Advanced Lung Adenocarcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Apr 3

PMID 37007097

Authors

Zhe-Rong Zheng

Hsiu-Ying Ku

Kun-Chieh Chen

Chun-Ju Chiang

Chih-Liang Wang

Chih-Yi Chen

Chun-Ming Tsai

Ming-Shyan Huang

Chong-Jen Yu

Jin-Shing Chen

Teh-Ying Chou

Wen-Chung Lee

Chun-Chieh Wang

Tsang-Wu Liu

Jiun-Yi Hsia

Gee-Chen Chang

Affiliations

Soon will be listed here.

Abstract

Introduction: Anaplastic lymphoma kinase (ALK) fusion mutation is more common in younger and never-smoking lung cancer patients. The association of smoking and ALK-tyrosine kinase inhibitors (TKIs) on overall survival (OS) of treatment-naïve ALK-positive advanced lung adenocarcinoma remains unclear in real-world.

Methods: This retrospective study evaluated all 33170 lung adenocarcinoma patients registered in the National Taiwan Cancer Registry from 2017 to 2019, of whom 9575 advanced stage patients had ALK mutation data.

Results: Among the 9575 patients, 650 (6.8%) patients had ALK mutation with the median follow-up survival time 30.97 months (median age, 62 years; 125 [19.2%] were aged ≥75 years; 357 (54.9%) females; 179 (27.5) smokers, 461 (70.9%) never-smokers, 10 (1.5%) with unknown smoking status; and 544 (83.7%) with first-line ALK-TKI treatment). Overall, of 535 patients with known smoking status who received first-line ALK-TKI treatment, never-smokers and smokers had a median OS of 40.7 months (95% confidence interval (CI), 33.1-47.2 months) and 23.5 months (95% CI, 11.5-35.5 months) (P=0.015), respectively. Among never-smokers, those who received first-line ALK-TKI treatment had a median OS of 40.7 months (95% CI, 22.7-57.8 months), while those ALK-TKI not as first-line treatment had a median OS of 31.7 months (95% CI, 15.2-42.8 months) (P=0.23). In smokers, the median OS for these patients was 23.5 months (95% CI, 11.5-35.5 months) and 15.6 months (95% CI, 10.2-21.1 months) (P=0.026), respectively.

Conclusions And Relevance: For patients with treatment-naïve advanced lung adenocarcinoma, the ALK test should be performed irrespective of smoking status and age. Smokers had shorter median OS than never-smokers among treatment-naïve-ALK-positive patients with first-line ALK-TKI treatment. Furthermore, smokers not receiving first-line ALK-TKI treatment had inferior OS. Further investigations for the first-line treatment of ALK-positive smoking advanced lung adenocarcinoma patients are needed.

Citing Articles

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.

De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C Front Immunol. 2025; 16:1515748.

PMID: 39995659 PMC: 11847692. DOI: 10.3389/fimmu.2025.1515748.

Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements.

Kim K, Kim K, Kang H, Shin A, Kim S, Park C Ther Adv Med Oncol. 2025; 17:17588359251316200.

PMID: 39926259 PMC: 11806492. DOI: 10.1177/17588359251316200.

Taiwan Nationwide Study of First-Line ALK-TKI Therapy in ALK-Positive Lung Adenocarcinoma.

Zheng Z, Wu J, Chiang C, Chen T, Chen K, Chu C Target Oncol. 2024; 19(6):941-955.

PMID: 39392550 DOI: 10.1007/s11523-024-01104-6.

References

Tseng C, Chiang C, Tseng J, Yang T, Hsu K, Chen K . EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 2017; 8(58):98384-98393. PMC: 5716737. DOI: 10.18632/oncotarget.21842. View

Tseng C, Tsuang B, Chiang C, Ku K, Tseng J, Yang T . The Relationship Between Air Pollution and Lung Cancer in Nonsmokers in Taiwan. J Thorac Oncol. 2019; 14(5):784-792. DOI: 10.1016/j.jtho.2018.12.033. View

Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C . Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev. 2010; 36 Suppl 3:S21-9. DOI: 10.1016/S0305-7372(10)70016-5. View

Vandenbroucke J, von Elm E, Altman D, Gotzsche P, Mulrow C, Pocock S . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007; 147(8):W163-94. DOI: 10.7326/0003-4819-147-8-200710160-00010-w1. View

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X. View

Peters S, Camidge D, Shaw A, Gadgeel S, Ahn J, Kim D . Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9):829-838. DOI: 10.1056/NEJMoa1704795. View

Wu Y, Zhou C, Hu C, Feng J, Lu S, Huang Y . Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15(2):213-22. DOI: 10.1016/S1470-2045(13)70604-1. View

Solomon B, Besse B, Bauer T, Felip E, Soo R, Camidge D . Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018; 19(12):1654-1667. DOI: 10.1016/S1470-2045(18)30649-1. View

Chiang C, Wang Y, Lee W . Taiwan's Nationwide Cancer Registry System of 40 years: Past, present, and future. J Formos Med Assoc. 2019; 118(5):856-858. DOI: 10.1016/j.jfma.2019.01.012. View

10.

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

11.

Friedlaender A, Banna G, Patel S, Addeo A . Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC. Curr Treat Options Oncol. 2019; 20(10):79. DOI: 10.1007/s11864-019-0675-9. View

12.

Aisner D, Sholl L, Berry L, Rossi M, Chen H, Fujimoto J . The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2017; 24(5):1038-1047. PMC: 7008001. DOI: 10.1158/1078-0432.CCR-17-2289. View

13.

Le Calvez F, Mukeria A, Hunt J, Kelm O, Hung R, Taniere P . TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005; 65(12):5076-83. DOI: 10.1158/0008-5472.CAN-05-0551. View

14.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

15.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

16.

Wu Y, Lu S, Lu Y, Zhou J, Shi Y, Sriuranpong V . Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018; 13(10):1539-1548. DOI: 10.1016/j.jtho.2018.06.012. View

17.

Britschgi C, Addeo A, Rechsteiner M, Delaloye R, Fruh M, Metro G . Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. Front Oncol. 2020; 10:1299. PMC: 7472246. DOI: 10.3389/fonc.2020.01299. View

18.

Condoluci A, Mazzara C, Zoccoli A, Pezzuto A, Tonini G . Impact of smoking on lung cancer treatment effectiveness: a review. Future Oncol. 2016; 12(18):2149-61. DOI: 10.2217/fon-2015-0055. View

19.

Pikor L, Ramnarine V, Lam S, Lam W . Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013; 82(2):179-89. DOI: 10.1016/j.lungcan.2013.07.025. View

20.

Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77. DOI: 10.1056/NEJMoa1408440. View